Changes in Characteristics,Treatment and Outcome in Patients with Hemorrhagic Stroke During COVID-19 |
| |
Authors: | Yuqi Chen Fan Xia Yunke Li Hao Li Lu Ma Xin Hu Chao You |
| |
Affiliation: | 2. Section of Neurosurgery, Department of Surgery, University of Chicago Medicine and Biological Sciences, Chicago, IL, USA;2. Department of Cardiology, Kocaeli Government Hospital, Gunes Street, 41300 Kocaeli, Turkey;2. Department of Medical and Surgical Science, University of Bologna, Italy;2. Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh, India;3. Clinical Epidemiology Unit, All India Institute of Medical Sciences, New Delhi, India;4. Department of Biotechnology, Ministry of Science & Technology, New Delhi, India;2. Second Clinical Medical College, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510120, China |
| |
Abstract: | Background and PurposeThe coronavirus disease 2019 (COVID-19) pandemic has had a comprehensive impact on healthcare services worldwide. We sought to determine whether COVID-19 affected the treatment and prognosis of hemorrhagic stroke in a regional medical center in mainland China.MethodsPatients with hemorrhagic stroke admitted in the Neurosurgery Department of West China Hospital from January 24, 2020, to March 25, 2020 (COVID-19 period), and from January 24, 2019, to March 25, 2019 (pre-COVID-19 period), were identified. Clinical characteristics, hospital arrival to neurosurgery department arrival time (door-to-department time), reporting rate of pneumonia and 3-month mRS (outcome) were compared.ResultsA total of 224 patients in the pre-COVID-19 period were compared with 126 patients in the COVID-19 period. Milder stroke severity was observed in the COVID-19 period (NIHSS 6 [2–20] vs. 3 [2–15], p = 0.005). The median door-to-department time in the COVID-19 period was approximately 50 minutes longer than that in the pre-COVID-19 period (96.5 [70.3–193.3] vs. 144.5 [93.8–504.5], p = 0.000). A higher rate of pneumonia complications was reported in the COVID-19 period (40.6% vs. 60.7%, p = 0.000). In patients with moderate hemorrhagic stroke, the percentage of good outcomes (mRS < 3) in the pre-COVID-19 period was much higher than that in the COVID-19 period (53.1% vs. 26.3%, p = 0.047).ConclusionsCOVID-19 may have several impacts on the treatment of hemorrhagic stroke and may influence the clinical outcomes of specific patients. Improvements in the treatment process for patients with moderate stroke may help to improve the overall outcome of hemorrhagic stroke during COVID-19. |
| |
Keywords: | |
本文献已被 ScienceDirect 等数据库收录! |
|